Vertex Pharmaceuticals Incorporated (VRTX) stock had a bullish inflow of $38.34 million worth of trades on uptick and an outflow of $29.35 million in downticks on Tuesday. The total uptick to downtick ratio stood at 1.31. The net money flow into the stock was $9 million. The money flow data, which is calculated as the dollar value of composite uptick minus the downtick trades indicated bullish. The block trades had a total money flow of $9.92 million. An inflow of $4.55 million block trade was recorded on downticks. $14.47 million of block trade during Uptick was observed, which shows continued buying by the smart money on every weakness. The total uptick to downtick ratio of block trades was 3.18 in favor of the bulls. However, Vertex Pharmaceuticals Incorporated (VRTX) stock traded down $0.47 , and reached $89.63, a drop of -0.52% over the previous day. On a weekly basis, the stock is 0.75%, over the previous weeks close.
The company Insiders own 1.8% of Vertex Pharmaceuticals Incorporated shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by -3.03% . Institutional Investors own 97.05% of Vertex Pharmaceuticals Incorporated shares. During last six month period, the net percent change held by insiders has seen a change of -3.03%. In an insider trading activity, The Securities and Exchange Commission has divulged that Boger Joshua S, director of Vertex Pharmaceuticals Inc / Ma, had unloaded 5,140 shares at an average price of $88.33 in a transaction dated on July 6, 2016. The total value of the transaction was worth $454,016.
Shares of Vertex Pharmaceuticals Incorporated appreciated by 3.61% during the last five trading days but lost 2.03% on a 4-week basis. Vertex Pharmaceuticals Incorporated is up 7.51% in the last 3-month period. Year-to-Date the stock performance stands at -28.77%.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX): On Tuesdays trading session , Opening price of the stock was $91.1 with an intraday high of $91.45. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $89.135. However, the stock managed to close at $89.63, a loss of 0.52% for the day. On the previous day, the stock had closed at $90.1. The total traded volume of the day was 1,548,387 shares.
Vertex Pharmaceuticals Incorporated (Vertex) is a global biotechnology company. The Company is engaged in the business of discovering, developing, manufacturing and commercializing small molecule drugs. The Company uses precision medicine approaches to create transformative drugs for patients with serious diseases in specialty markets. Vertexs business is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF). It is also engaged in other research and early-stage development programs, including programs in the areas of oncology and neurology. The Companys product candidates include KALYDECO (ivacaftor), Lumacaftor in combination with Ivacaftor, VX-661 in combination with Ivacaftor, VX-803, VX-970 and VX-222. The Companys product KALYDECO is available in the market.